Related Experiment Videos
TSH suppression by octreotide in differentiated thyroid carcinoma
C L Maini1, R Sciuto, A Tofani
1Nuclear Medicine Department, Regina Elena, National Cancer Institute, Rome, Italy.
Clinical Endocrinology
|March 1, 1994
Summary
Adding octreotide to L-thyroxine significantly enhances thyroid-stimulating hormone (TSH) suppression in differentiated thyroid cancer patients. This combined therapy offers a faster and safer alternative for TSH management.
Area of Science:
- Endocrinology
- Oncology
- Nuclear Medicine
Background:
- Elevated thyroid-stimulating hormone (TSH) levels pose risks for patients with differentiated thyroid carcinoma post-thyroidectomy.
- Shortening the period of high TSH is crucial for effective radioiodine (131I) therapy and cancer management.
Purpose of the Study:
- To evaluate the efficacy of combining octreotide with L-thyroxine in accelerating TSH suppression.
- To assess the safety and effectiveness of this combined therapy in differentiated thyroid carcinoma patients undergoing total body scan with 131I.
Main Methods:
- A study involving fourteen thyroidectomized patients divided into four groups based on L-thyroxine dosage and octreotide addition.
- Serum TSH, T3, and T4 levels were monitored at various time points after radioiodine administration.
- One group received L-thyroxine alone, while others received a combination of L-thyroxine and octreotide.
Main Results:
- TSH suppression was significantly slower with L-thyroxine alone compared to combined therapy.
- The combination of L-thyroxine and octreotide demonstrated a more rapid and complete TSH inhibition.
- Group 4 (higher L-thyroxine dose plus octreotide) showed the most pronounced TSH reduction, with 88% decrease in 14 days and complete suppression in 30 days.
Conclusions:
- Combined octreotide and L-thyroxine therapy significantly enhances TSH suppression compared to L-thyroxine alone.
- This combined approach is safe and provides a valuable alternative for managing TSH levels, especially when high L-thyroxine doses are not feasible or in advanced illness.